Dianthus Therapeutics, Inc. released an updated corporate presentation containing interim responder analysis data for the first 40 patients who completed Part A of the Phase 3 CAPTIVATE trial of claseprubart in chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. is a biotechnology company focused on developing therapeutic solutions for inflammatory and inflammatory-related diseases.
